March 6, 2026
USPTO grants U.S. Patent Nos. 12,540,176, 12,540,177, and 12,552,860, covering three distinct anti-IL-1α antibodies and significantly expanding XBiotech’s proprietary IP estate.
AUSTIN, Texas – 06 Mar 2026- XBiotech Inc. (NASDAQ: XBIT), a fully integrated global biopharmaceutical company pioneering the discovery and development of True Human™ therapeutic antibodies, today announced that the U.S. Patent and Trademark Office (USPTO) has granted three new patents — U.S. Patent Nos. 12,540,176; 12,540,177; and 12,552,860 — each titled “True Human Antibody Specific for Interleukin 1 Alpha.” The patents cover three structurally distinct human monoclonal antibodies in XBiotech’s next-generation anti-IL-1α program.
Each of the three patented antibodies features a high-affinity antigen-binding variable region targeting IL-1α, combined with a constant region optimized for therapeutic potency across a range of inflammatory disease settings.
IL-1α is a key driver of pathological inflammation across a broad spectrum of serious diseases, including inflammatory skin conditions, cardiovascular disease, rheumatological disorders, and cancer. XBiotech's True Human™ platform derives antibodies directly from individuals with natural immunity to disease. Unlike conventional biologics, this process requires no genetic modification or in vitro affinity engineering, and the company believes it produces antibodies with superior safety, tolerability, and immunogenic compatibility.
The trio of patents represents a significant expansion of XBiotech's proprietary IP estate and builds on the company's deep expertise in anti-IL-1α science. That expertise was established through the development of bermekimab, the first True Human™ antibody targeting IL-1α, which was acquired by Janssen Biotech in 2019. XBiotech retained the right to develop next-generation anti-IL-1α therapeutics, and these patents reflect the continued advancement of that program.
Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects.
By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better.
